Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE). Despite the improvement in the field, up to one-third of LN patients still do not respond to initial immunosuppressive treatment. There are many inflammatory cytokines/chemokines have been shown as LN biomarkers.In this study, we assessed levels of urinary Interleukin-6 (IL-6), Interferon-inducible protein-10 (IP-10), Vascular Endothelial Growth Factor (VEGF) and Tumor necrosis factor like weak inducer of apoptosis (TWEAK) during an induction phase (baseline, 1- and 3-month of the treatment) in 59 LN patients who received various immunosuppressants (intravenous cyclophosphamide (IVCY), mycophenolate mofetil (MMF) and tacrolimus. The resutls showed significant reduce of IL-6, IP-10 and VEGF were seen in responder patients (IL-6, IP-10 and VEGF in 3-month (IL-6: baseline 16.18(2.44-37.37) pg/mg Creatinine, 3-month 3.82(0.63-13.25) pg/mg Creatinine, p=0.02, IP-10: baseline 83.65(25.00-165.01) pg/mg Creatinine, 3-month 33.85(12.97-95.58) pg/mg Creatinine, p= 0.04 and VEGF: baseline 255.95(108.36-402.99), 3-month 195.06(134.84-297.90), p = 0.04). These results may use for drug monitoring and predict respond to treatment. However we not found the different between IVCY, MMF, and tacrolimus in effect of cytokines reduction.In this study, decreases of the urinary biomarkers responding to treatments were observed. Each of treatments showed different characteristics of lowering the urinary biomarkers. Future studies with a larger number of patients are required to elucidate the findings and to prove if these urinary biomarkers are useful for personalized medicine. Especially, obvious decrements of the urinary biomarkers at, IL-6, IP-10 and VEGF can be useful to indicate the treatment efficiency in LN patients